Document:

<Page>
                                                                    Exhibit 10.3

[LETTERHEAD]

                                                                  CONFORMED COPY

                                Dated 26 MAY 2004

                            BUNGE FINANCE EUROPE B.V.
                                   as Borrower

                                      WITH

                                  HSBC BANK PLC
                                 ACTING AS AGENT

                  --------------------------------------------
                               AMENDMENT AGREEMENT
                                  RELATING TO A
                  MULTICURRENCY REVOLVING FACILITIES AGREEMENT
                                DATED 28 MAY 2003
                  --------------------------------------------

<Page>

THIS AGREEMENT is dated 26 May 2004 and made between:

(1)    BUNGE FINANCE EUROPE B.V. a private company with limited liability
       (BESLOTEN VENNOOTSCHAP MET BEPERKTE AANSPRAKELIJKHEID) incorporated under
       the laws of The Netherlands having its seat (STATUTAIRE ZETEL) at
       Rotterdam, The Netherlands and its registered office at 11720 Borman
       Drive, St. Louis, Missouri, 63146, United States and registered with the
       Chamber of Commerce (KAMER VAN KOOPHANDE) in Rotterdam under number
       24347428 (the "BORROWER");

(2)    THE LENDERS (as defined in the Original Facility Agreement); and

(3)    HSBC BANK PLC as agent of the Lenders (the "AGENT").

RECITALS:

(A)    We refer to the US $650,000,000 Multicurrency Revolving Facilities
       Agreement dated 28 May 2003 (as may be amended and restated from time to
       time, the "ORIGINAL FACILITY AGREEMENT") between the Borrower, the Agent,
       BNP Paribas, CCF and Societe Generale as mandated lead arrangers and the
       lenders referred to therein;

(B)    Pursuant to Clause 3 of the Original Facility Agreement, the Borrower has
       given notice to the Agent as an Extension Request in relation to Facility
       A;

(C)    In connection with the extension of the Final Maturity Date of Facility
       A, the Lenders have agreed to amend certain provisions of the Original
       Facility Agreement; and

(D)    Accordingly, the parties hereto desire to amend certain provisions of the
       Original Facility Agreement as set out below.

IT IS AGREED as follows:

1.     DEFINITIONS AND INTERPRETATION

1.1    DEFINITIONS
       In this Agreement:

       "AMENDED AGREEMENT" means the Original Facility Agreement, as amended by
       this Agreement.

       "EFFECTIVE DATE" means 26 May 2004, provided that on or before such date
       the Agent has received each of the documents listed in Schedule 1
       (CONDITIONS PRECEDENT) in a form and substance satisfactory to the Agent.

1.2    INCORPORATION OF DEFINED TERMS

       (a)    Unless a contrary indication appears, a term used in any other
              Finance Document or in any notice given under or in connection
              with any Finance Document has the same meaning in that Finance
              Document or notice as in this Agreement.

       (b)    The principles of construction set out in the Original Facility
              Agreement shall have effect as if set out in this Agreement.

                                      -1-
<Page>

1.3    CLAUSES

       (a)    In this Agreement any reference to a "Clause" or "Schedule" is,
              unless the context otherwise requires, a reference to a Clause or
              Schedule of this Agreement.

       (b)    Clause and Schedule headings are for ease of reference only.

2.     AMENDMENT OF THE ORIGINAL FACILITY AGREEMENT

       With effect from the Effective Date the Original Facility Agreement shall
       be amended as set out in Schedule 2 (AMENDMENTS TO ORIGINAL FACILITY
       AGREEMENT).

3.     EXTENSION OF FACILITY A FINAL MATURITY DATE

       With effect from the Effective Date, it is hereby agreed that pursuant to
       clause 3 (EXTENSION OF FACILITY) of the Original Facility Agreement, the
       Final Maturity Date for Facility A shall be extended to the date falling
       364 days from the date hereof.

4.     REPRESENTATIONS

       The Borrower makes the Repeating Representations as if each reference in
       those representations to "this Agreement" includes a reference to (a)
       this Agreement and (b) the Amended Agreement.

5.     CONTINUITY AND FURTHER ASSURANCE

5.1    CONTINUING OBLIGATIONS

       The provisions of the Finance Documents shall, save as amended in this
       Agreement, continue in full force and effect.

5.2    FURTHER ASSURANCE

       The Borrower shall, at the request of the Agent and at its own expense,
       do all such acts and things necessary or desirable to give effect to the
       amendments effected or to be effected pursuant to this Agreement.

6.     FEES, COSTS AND EXPENSES

6.1    ARRANGEMENT/FRONT END FEES

       The Borrower shall pay the fees set out in the Mandate Letter dated 21
       April 2004 within five Business Days of the Effective Date.

6.2    TRANSACTION EXPENSES

       The Borrower shall promptly on demand pay the Agent the amount of all
       costs and expenses (including legal fees) reasonably incurred by it in
       connection with the negotiation, preparation, printing and execution of
       this Agreement and any other documents referred to in this Agreement.

6.3    ENFORCEMENT COSTS

       The Borrower shall, within three Business Days of demand, pay to each
       Finance Party the amount of all costs and expenses (including legal fees)
       incurred by that Finance

                                      -2-
<Page>

       Party in connection with the enforcement of, or the preservation of any
       rights under this Agreement.

6.4    STAMP TAXES

       The Borrower shall pay and, within three Business Days of demand,
       indemnify each Finance Party against any cost, loss or liability that a
       Finance Party incurs in relation to all stamp duty, registration and
       other similar Taxes payable in respect of this Agreement.

7.     MISCELLANEOUS

7.1    INCORPORATION OF TERMS

       The provisions of clause 33 (PARTIAL INVALIDITY), clause 34 (REMEDIES AND
       WAIVERS), clause 37 (GOVERNING LAW) and clause 38 (ENFORCEMENT) of the
       Original Facility Agreement shall be incorporated into this Agreement as
       if set out in full in this Agreement and as if references in those
       clauses to "this Agreement" are references to this Agreement.

7.2    DESIGNATION AS FINANCE DOCUMENT

       The Borrower, the Agent and the Lenders designate this Agreement as a
       Finance Document by execution of this Agreement for the purposes of the
       definition of Finance Document in the Original Facility Agreement.

7.3    COUNTERPARTS

       This Agreement may be executed in any number of counterparts, and this
       has the same effect as if the signatures on the counterparts were on a
       single copy of this Agreement.

THIS AGREEMENT has been entered into on the date stated at the beginning of this
Agreement.

                                      -3-
<Page>

                                   SCHEDULE 1

                              CONDITIONS PRECEDENT

1.     BORROWER

       (a)    A copy of the constitutional documents of the Borrower, or a
              certificate from an authorised signatory of the Borrower
              certifying that the constitutional documents have not been amended
              or restated since the date of the Original Facility Agreement.

       (a)    A copy of a resolution of the board of directors of the Borrower:

              (i)    approving the terms of, and the transactions contemplated
                     by, this Agreement and resolving that it execute this
                     Agreement;

              (ii)   authorising a specified person or persons to execute this
                     Agreement on its behalf; and

              (iii)  authorising a specified person or persons, on its behalf,
                     to sign and/or despatch all documents and notices to be
                     signed and/or despatched by it under or in connection with
                     this Agreement.

       (b)    A specimen of the signature of each person authorised by the
              resolution referred to in paragraph (b) above.

       (c)    A shareholder resolution of the Borrower, approving the terms of,
              and the transactions contemplated by this Agreement.

       (d)    A certificate of an authorised signatory of the Borrower
              certifying that each copy document relating to it specified in
              this Schedule 1 is correct, complete and in full force and effect
              as at a date no earlier than the date of this Agreement.

2.     PARENT

       (a)    A certificate of an authorised signatory of the Parent confirming
              the prevalent S&P and Moody's Ratings of the Parent on the
              Effective Date.

3.     LEGAL OPINIONS

       (a)    A legal opinion of Clifford Chance LLP, legal advisers to the
              Agent as to matters of English law, substantially in the form
              distributed to the Lenders prior to signing this Agreement.

       (b)    A legal opinion of Clifford Chance LLP, legal advisers to the
              Agent as to matters of Dutch law, substantially in the form
              distributed to the Lenders prior to signing this Agreement.

                                      -4-
<Page>

       (c)    A legal opinion of Winston & Strawn LLP as to matters of New York
              law, opining notably on the continuing validity and enforceability
              of the Parent Guaranty.

                                      -5-
<Page>

                                   SCHEDULE 2

                    AMENDMENTS TO ORIGINAL FACILITY AGREEMENT

1.     The following to be inserted after Clause 12.3 (AGENCY FEE) of the
       Original Facility Agreement as Clause 12.4:

       "12.4 FACILITY A UTILISATION FEE

       A utilisation fee will accrue on the aggregate principal amount of
       Facility A Loans in respect of each day on which the aggregate principal
       amount of Facility A Loans exceed 50 per cent. of the Facility A
       Commitment. This fee will accrue from 26 May 2004 until the relevant
       Final Maturity Date. The rate of the fee will be 0.075 per cent. per
       annum. The Borrower agrees to pay the fee to each Lender pro rata in
       arrear at three-month intervals from 26 May 2004 and on the Final
       Maturity Date in respect of Facility A."

2.     The following to be inserted at the end of sub-clause (a) of Clause 35.2
       (EXCEPTIONS) after the word "Lenders.":

       "PROVIDED THAT, an amendment or waiver described in sub-clauses (ii),
       (iii) and (iv) above, shall only require the prior consent of all of the
       Lenders participating in the Facility affected by such amendment or
       waiver."

3.     Paragraph 1.1 of Schedule 1 (APPLICABLE MARGIN) of the Original Facility
       Agreement shall be deleted and replaced with the following:

       "1.1   In relation to Facility A, the Applicable Margin is 1.00 per cent.
              per annum unless S&P and/or Moody's are publishing in respect of
              the Parent a long term unsecured debt rating, in which case the
              Applicable Margin is the percentage rate per annum that
              corresponds to that rating, as in effect from time to time as set
              out in the following table:

<Table>
<Caption>
------------------------------------- ---------------------------------- -----------------------------------
             S&P RATING                        MOODY'S RATING                    APPLICABLE MARGIN
                                                                                   (% PER ANNUM)
------------------------------------- ---------------------------------- -----------------------------------
<S>                                   <C>                                <C>
           BBB+ or above                        Baa1 or above                           0.45
------------------------------------- ---------------------------------- -----------------------------------
                BBB                                 Baa2                                0.65
------------------------------------- ---------------------------------- -----------------------------------
                BBB-                                Baa3                                0.80
------------------------------------- ---------------------------------- -----------------------------------
            BB+ or below                        Ba1 or below                           1.00"
------------------------------------- ---------------------------------- -----------------------------------
</Table>

4.     Schedule 2 (THE ORIGINAL LENDERS) shall be deleted and replaced with the
       following:

                                      -6-
<Page>

                                   "SCHEDULE 2

                                   THE LENDERS

<Table>
<Caption>
NAME OF LENDER                                           FACILITY A COMMITMENT          FACILITY B COMMITMENT
--------------                                           ---------------------          ---------------------
<S>                                                              <C>                            <C>
CDC IXIS                                                         35,000,000.00                  15,000,000.00

BNP Paribas S.A.                                                 24,500,000.00                  10,500,000.00

Societe Generale                                                 24,500,000.00                  10,500,000.00

WestLB AG, Paris Branch                                          24,500,000.00                  10,500,000.00

Barclays Bank PLC                                                22,750,000.00                   9,750,000.00

ABN AMRO Bank N.V. Paris Branch                                  18,500,000.00                   7,500,000.00

Bayerische Hypo-und Vereinsbank AG, Munich                       18,500,000.00                   7,500,000.00

Fortis Bank (Nederland) N.V.                                     18,500,000.00                   7,500,000.00

ING Bank N.V.                                                    18,500,000.00                   7,500,000.00

BBVA Ireland plc                                                 17,500,000.00                   7,500,000.00

Credit Agricole d'Ile de France                                  17,500,000.00                   7,500,000.00

Natexis Banques Populaires                                       17,500,000.00                   7,500,000.00

Raiffeisen Zentralbank Oesterreich AG                            17,500,000.00                   7,500,000.00

HSBC Bank plc                                                    24,500,000.00                  10,500,000.00

Cooperatieve Centrale Raiffeisen-                                15,000,000.00                   6,000,000.00
Boerenleenbank B.A. trading as
Rabobank International London Branch

Sanpaolo IMI S.p.A.                                              13,500,000.00                   3,750,000.00

Landesbank Rheinland-Pfalz - Girozentrale                        14,000,000.00                   6,000,000.00

KBC Bank N.V.                                                    11,500,000.00                   4,500,000.00

Banca Nazionale del Lavoro International SA                               0.00                   3,750,000.00

Banca  Nazionale del Lavoro  S.p.A. - New York                    9,750,000.00                           0.00
Branch

KfW                                                               9,750,000.00                   3,750,000.00

Scotiabank Europe plc                                             9,750,000.00                   3,750,000.00

Standard Chartered Bank PLC                                       9,750,000.00                   3,750,000.00

                                      -7-
<Page>

ANZEF Limited                                                     8,750,000.00                   3,750,000.00

Banca Intesa, France                                              8,750,000.00                   3,750,000.00

Credit Suisse                                                     8,750,000.00                   3,750,000.00

Unicredito Italiano SpA - London Branch                           8,750,000.00                   3,750,000.00

Banque Artesia Nederland N.V.                                     8,000,000.00                   3,000,000.00

Banca Monte dei Paschi di Siena S.p.A., New                       7,000,000.00                   3,000,000.00
York Branch

Morgan Stanley Bank                                               5,250,000.00                   2,250,000.00

BRED Banque Populaire, Paris                                      3,500,000.00                   1,500,000.00

State Bank of India, Antwerp                                      3,500,000.00                   1,500,000.00

Bank fur Arbeit und Wirtschaft AG                                         0.00                   3,750,000.00

Banco Espanol de Credito S.A.                                             0.00                   3,000,000.00

TOTALS:                                                         455,000,000.00                 195,000,000.00
</Table>

                                      -8-
<Page>

                                                        SIGNATURES

THE BORROWER

BUNGE FINANCE EUROPE B.V.

By:       MORRIS KALEF

THE AGENT

HSBC BANK PLC

By:       PAUL THOMPSON

THE LENDERS

CDC IXIS

By:       WESLEY FALLAN

BNP PARIBAS S.A.

By:      CAMERON LETTERS AND RAQUEL LATUEF

SOCIETE GENERALE

By:      A.-DOMINQUE BERETTI

WEST LB AG, PARIS BRANCH

By:       KHALED OSMAN  AND MARIE-LAURE SANTUCCI

BARCLAYS BANK PLC

By:        DES POTTER

ABN AMRO BANK N.V. PARIS BRANCH

By:      WESLEY FALLAN

                                      -9-
<Page>

BAYERISCHE HYPO-UND VEREINSBANK AG, MUNICH

By:      R. GLOECKNER AND R. HANIG

FORTIS BANK (NEDERLAND) N.V.

By:      J. AE OPTEN NOORT AND J. J. BRONSWIFT

ING BANK N.V.

By:         PAUL VAN HEERDE AND LARS VRIENS

BBVA IRELAND PLC

By:      PABLO VALLEJO

CREDIT AGRICOLE D'ILE DE FRANCE

By:     WESLEY FALLAN

NATEXIS BANQUES POPULAIRES

By:       WESLEY FALLAN

RAIFFEISEN ZENTRALBANK OESTERREICH AG

By:       WOLFGANG RACHBAUER AND L GERSCHNER

HSBC BANK PLC

By:        TRACY LOWRIE

COOPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A. TRADING
AS RABOBANK INTERNATIONAL LONDON BRANCH

By:        T.M. STANLEY AND S. TYLER

                                      -10-
<Page>

SANPAOLO IMI S.P.A.

By:          CATHY R. LESSE AND RENATO CARDUCCI

LANDESBANK RHEINLAND-PFALZ - GIROZENTRALE

By:           STEFAN GILSDORF AND MARCO DE ALMEIDA PINTO

KBC BANK N.V.

By:          PATRICK DES MAREZ AND CLAUDE DEROOSE

BANCA NAZIONALE DEL LAVORO INTERNATIONAL SA

By:          MARCELLO NICOLETTI AND FRANCESCO ZACCHINO

BANCA NAZIONALE DEL LAVORO SPA, NEW YORK BRANCH

By:         FRANCESCO DI MARIO AND CARLO VECCHI

KFW

By:         DR. AXEL RADU AND SVEN WABBELS

SCOTIABANK EUROPE PLC

By:           T.A. BURCHETT

STANDARD CHARTERED BANK PLC

By:           D.A. HILL AND S. WILLIAMS

ANZEF LIMITED

By:            R.J. HEYHOE

                                      -11-
<Page>

BANCA INTESA, FRANCE

By:          WESLEY FALLAN

CREDIT SUISSE

By:          GIANNI SARGENTI AND MANUELA GENOUD

UNICREDITO ITALIANO SPA - LONDON BRANCH

By:        P.W. JARMAN AND J.S. CHISNELL

BANQUE ARTESIA NEDERLAND N.V.

By:           G.P. HERTING AND JORIS VAN HELLEPUTTE

BANCA MONTE DEI PASCHI DI SIENA S.P.A., NEW YORK BRANCH

By:            SERGE M. SODAK AND BRIAN R. LANDY

MORGAN STANLEY BANK

By:         DANIEL TWENGE

BRED BANQUE POPULAIRE, PARIS

By:              WESLEY FALLON

STATE BANK OF INDIA, ANTWERP

BY:               PRAVIN M. SONAVANE

BANK FUR ARBEIT UND WIRTSCHAFT AG

By:               H. RAFFAY AND U. KUNZ

BANCO ESPANOL DE CREDITO S.A.

By:           PERE JORI DEL AMO AND MERCEDES MUNT-CARCELLER BANULS

                                      -12-QuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 4.1    
    

FIRST SUPPLEMENTAL INDENTURE  

        THIS FIRST SUPPLEMENTAL INDENTURE, dated as of June 15, 2004 (this "First Supplemental Indenture"), to the Indenture (as defined below), among Inverness
Medical Innovations, Inc., a Delaware corporation (the "Issuer"), the Guarantors (as defined in the Indenture), Advantage Diagnostics Corporation, a Delaware corporation (the "Additional
Guarantor") and U.S. Bank Trust National Association, as Trustee (the "Trustee"). 

RECITALS  

        WHEREAS, the Issuer has issued its 83/4% Senior Subordinated Notes due 2012 (the "Notes") in the aggregate principal amount of $150,000,000 under
and pursuant to the Indenture, dated as of February 10, 2004 (the "Indenture"), among the Issuer, the Guarantors listed therein and the Trustee. 

        WHEREAS,
unless the context requires otherwise, all capitalized terms used but not otherwise defined herein will have the meanings ascribed thereto in the Indenture. 

        WHEREAS,
the Additional Guarantor has become a Restricted Subsidiary and pursuant to Section 4.14 of the Indenture is entering into this First Supplemental Indenture to thereby
become a Guarantor as provided in Article Eleven of the Indenture. 

        WHEREAS,
pursuant to Section 9.01(5) of the Indenture, the Issuer, the Guarantors, the Additional Guarantor and the Trustee may enter into this First Supplemental Indenture
without the consent of any Holder. 

AGREEMENT  

        NOW, THEREFORE, for and in consideration of the premises and the mutual covenants and agreements hereinafter set forth, the parties hereto agree as follows: 

ARTICLE I

ADDITIONAL GUARANTOR  

        Section 1.01.    Additional Guarantor.    The Additional Guarantor hereby agrees, jointly and severally with all of
the Guarantors, to unconditionally guarantee all of the Issuer's obligations under the Notes and the Indenture as a Guarantor thereunder on the terms and subject to the conditions set forth in the
Indenture and to be bound by all provisions of the Indenture applicable to a Guarantor. 

        Section 1.02.    First Supplemental Indenture.    This First Supplemental Indenture is supplemental to, and is entered
into, in accordance with Section 9.01 of the Indenture, and except as modified, amended and supplemented by this First Supplemental Indenture, the provisions of the Indenture will remain in
full force and effect. 

ARTICLE II

MISCELLANEOUS  

        Section 2.01.    Duplicates.    All parties may sign any number of copies of this First Supplemental Indenture. Each
signed copy or counterpart shall be an original, but all of them together shall represent the same agreement. 

        Section 2.02.    Successors and Assigns.    All agreements of the Issuer, the Guarantors and the Additional Guarantor
in this First Supplemental Indenture shall bind their respective successors. All agreements of the Trustee in this First Supplemental Indenture shall bind its successor. 

        Section 2.03.    Severability.    To the extent permitted by applicable law, in case any one or more of the provisions
in this First Supplemental Indenture shall be held invalid, illegal or unenforceable, in any respect for any reason, the validity, legality and enforceability of any such provision in every other
respect and of the remaining provisions shall not in any way be affected or impaired thereby, it being intended that all of the provisions hereof shall be enforceable to the full extent permitted by
law. 

        Section 2.04.    Governing Law.    This First Supplemental Indenture will be governed by and construed in accordance
with the laws of the State of New York. 

 

        IN
WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of the date first written above. 

	 	 	INVERNESS MEDICAL INNOVATIONS, INC.,

as Issuer
	

 	
 	

By:	

/s/  CHRISTOPHER LINDOP      
 Name:  Christopher Lindop

Title:    Chief Financial Officer
	

 	
 	

APPLIED BIOTECH, INC.,

FOREFRONT DIAGNOSTICS, INC., INNOVATIONS RESEARCH, LLC,

INVERNESS MEDICAL INTERNATIONAL HOLDING CORP.,

INVERNESS MEDICAL INTERNATIONAL HOLDING CORP. II,

INVERNESS MEDICAL, INC.,

MORPHEUS ACQUISITION CORP.,

OSTEX INTERNATIONAL, INC.,

UNIPATH DIAGNOSTICS, INC.,

UNIPATH ONLINE, INC., and

WAMPOLE LABORATORIES, LLC,

as Guarantors
	

 	
 	

By:	

/s/  ANTHONY J. BERNARDO      
 Name:  Anthony J. Bernardo

Title:    President, President, Manager,

             President, President, President, President,

             President, Vice President,

             President, and Manager, respectively
	

 	
 	

SELFCARE TECHNOLOGY, INC.,

as a Guarantor
	

 	
 	

By:	

/s/  DUANE L. JAMES      
 Name:  Duane L. James

Title:    Treasurer
	

 	
 	

ADVANTAGE DIAGNOSTICS CORPORATION,

as Additional Guarantor
	

 	
 	

By:	

/s/  ANTHONY J. BERNARDO      
 Name:  Anthony J. Bernardo

Title:    President
	

 	
 	

U.S. BANK TRUST NATIONAL ASSOCIATION,

as Trustee
	

 	
 	

By:	

/s/  CHERYL L. CLARKE      
 Name:  Cheryl L. Clarke

Title:    Assistant Vice President

3

QuickLinks

EXHIBIT 4.1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]